Verrica Pharmaceuticals Files 8-K on Financials
Ticker: VRCA · Form: 8-K · Filed: Mar 11, 2025 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | Mar 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, financial-statements
Related Tickers: VRCA
TL;DR
VRCA filed an 8-K for financial updates, no major news.
AI Summary
Verrica Pharmaceuticals Inc. filed an 8-K on March 11, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, but does not specify any new material events or transactions.
Why It Matters
This filing provides an update on Verrica Pharmaceuticals' financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine update on financial condition and does not report any new material events, debt, or significant changes.
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — Registrant
- 001-38529 (company) — SEC File Number
- 46-3137900 (company) — IRS Employer Identification No.
- March 11, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Verrica Pharmaceuticals Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on March 11, 2025.
What is Verrica Pharmaceuticals Inc.'s state of incorporation?
Verrica Pharmaceuticals Inc. is incorporated in Delaware.
What is the principal executive office address for Verrica Pharmaceuticals Inc.?
The principal executive office address is 44 W. Gay St., Suite 400, West Chester, PA 19380.
Does this filing report any new material events or transactions?
Based on the provided text, this filing primarily concerns results of operations and financial condition, and does not explicitly mention any new material events or transactions beyond routine financial reporting.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 11, 2025 regarding Verrica Pharmaceuticals Inc. (VRCA).